Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Cantor Fitzgerald
UBS
Novartis
QuintilesIMS
McKinsey
Argus Health
Healthtrust
US Army
Farmers Insurance

Generated: February 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,193,195

« Back to Dashboard

Which drugs does patent 8,193,195 protect, and when does it expire?

Patent 8,193,195 protects VIIBRYD and is included in one NDA.

This patent has fifty-eight patent family members in twenty-nine countries.
Summary for Patent: 8,193,195
Title:Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Abstract: The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine- , crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, fibromyalgia, sleeping disorders, psychiatric disorders, cerebral infarct, tension, for the therapy of side-effects in the treatment of hypogonadism, secondary amenorrhea, premenstrual syndrome and undesired puerperal lactation.
Inventor(s): Bathe; Andreas (Darmstadt, DE), Helfert; Bernd (Ober-Ramstadt, DE), Neuenfeld; Steffen (Messel, DE), Kniel; Heike (Heppenheim, DE), Bartels; Matthias (Darmstadt, DE), Rudolph; Susanne (Dieburg, DE), Bottcher; Henning (Darmstadt, DE)
Assignee: Merck Patentgesellschaft (Darmstadt, DE)
Application Number:12/945,272
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 8,193,195

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan Sales Llc VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-001 Jan 21, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) ➤ Sign Up
Allergan Sales Llc VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-002 Jan 21, 2011 RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) ➤ Sign Up
Allergan Sales Llc VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-003 Jan 21, 2011 RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,193,195

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
01113647Jun 19, 2001

Non-Orange Book US Patents Family Members for Patent 8,193,195

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,236,804 Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride ➤ Sign Up
7,381,726 Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride ➤ Sign Up
9,624,204 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride ➤ Sign Up
8,673,921 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride ➤ Sign Up
7,834,020 Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride ➤ Sign Up
7,981,894 Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride ➤ Sign Up
8,927,552 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride ➤ Sign Up
8,921,375 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride ➤ Sign Up
8,318,744 Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,193,195

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Ukraine 76758 ➤ Sign Up
Slovakia 288334 ➤ Sign Up
Slovakia 288162 ➤ Sign Up
Slovakia 162004 ➤ Sign Up
Russian Federation 2303598 ➤ Sign Up
Russian Federation 2004100824 ➤ Sign Up
Portugal 1397357 ➤ Sign Up
Poland 208708 ➤ Sign Up
Poland 364576 ➤ Sign Up
New Zealand 530642 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Teva
Covington
Argus Health
Colorcon
Cantor Fitzgerald
Daiichi Sankyo
Johnson and Johnson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot